secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2023-05-01T23:59:59+00:00
Accession:  0001104659-23-053502
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics appoints John Doyle as CFO effective May 1, 2023
-----------------------------------------------------------------------

- John Doyle appointed CFO effective May 1; succeeds interim CFO Andrew Einhorn, who serves until May 15.
- Base salary $415k, target bonus 40%, signing bonus $40k; equity grants: 109,824 options and 109,824 RSUs vesting over 4 years.
- Prior roles include CFO of 4D Pharma and Chiasma, VP Finance at Verastem Oncology.
- Severance: 9 months base salary on termination without cause; 12 months on change in control plus accelerated equity vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465923053502/0001104659-23-053502-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465923053502/tm2314004d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-053502

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer